Sep 1, 2026 04:39PM

Aug 7, 2026 04:01PM

Jul 15, 2026 08:00AM

Jul 15, 2026 08:00AM

May 15, 2026 08:00AM

May 11, 2026 04:01PM

May 11, 2026 04:01PM aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

Mar 6, 2026 12:19PM

Mar 6, 2026 08:31AM

Mar 5, 2026 04:01PM

Feb 3, 2026 08:01AM

Feb 3, 2026 08:00AM

Nov 6, 2025 04:01PM

Sep 15, 2025 12:55PM Lucid Capital Markets Downgrades aTyr Pharma (ATYR) to Neutral

Sep 15, 2025 12:23PM

Sep 15, 2025 11:57AM

Sep 15, 2025 10:58AM

Sep 15, 2025 07:30AM

Sep 15, 2025 07:30AM

Jun 4, 2025 08:03AM

Jun 4, 2025 08:00AM aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

Apr 23, 2025 09:43AM

Mar 14, 2025 06:51AM

Mar 14, 2025 06:40AM

Mar 13, 2025 04:01PM

Dec 21, 2024 10:00AM

Nov 19, 2024 08:07AM

Oct 29, 2024 07:27AM H.C. Wainwright Reiterates Buy Rating on aTyr Pharma (ATYR)

Oct 21, 2024 07:35AM

329,989 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All